Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Coronavirus Stock Opko Health Plunged by 13% on Friday

By Eric Volkman – Jul 31, 2020 at 6:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's latest set of earnings, it seems, wasn't outstanding enough for investors.

What happened

Opko Health (OPK) -- considered a coronavirus stock thanks to its BioReference Laboratories, which has diagnostics products that test for the globe's top health threat at the moment -- closed nearly 13% lower on Friday. 

The apparent cause was the company's Q2 fiscal 2020 results, which clearly disappointed investors even though the healthcare company notched beats on both the top and bottom lines.

Medical professional writing on a document held with a clipboard.

Image source: Getty Images.

So what

Opko's revenue rose a sturdy 33% on a year-over-year basis to just over $301 million, thanks in no small part to the dramatic expansion of BioReference's business during the coronavirus pandemic.

On the bottom line, the company flipped to a net profit of $33.7 million ($0.05 per share), from the year-ago loss of almost $60 million.

Both headline numbers thrashed analyst projections. On average, prognosticators following the stock were modeling around $216 million in revenue, and a per-share net loss of $0.07.

Now what

A sell-off is typically the opposite of what happens when a company delivers an estimate-trouncing quarter. With Opko, investors might be concerned that sales of the company's products (as opposed to services) were relatively weak, even though this revenue stream is much thinner. 

They might also be worried that the company did not proffer guidance, although this is not unusual for companies in any sector during these very uncertain times.

Whatever the reason or reasons, the very negative reaction seems unwarranted. It won't be surprising to see Opko stock rise again, particularly on good news.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.